Company intelligence / Profile preview
Abeona Therapeutics Inc.
Cleveland, Ohio, United Statesabeonatherapeutics.com ↗
- Ownership
- Public · ABEO
- Development stage
- Phase 3
01
Overview
Abeona received FDA approval for ZEVASKYN (prademagene zamikeracel) on April 29, 2025, the first and only cell-based gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). The approval followed positive Phase 3 VIITAL™ study results where both co-primary endpoints were met, showing >50% wound healing and pain reduction at six months. The company plans commercial launch in Q3 2025.
- Therapeutic areas
- OphthalmologyRare DiseasesNeurology
- Modalities
- Cell therapyGene therapyAAV-based gene therapies
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
Ultragenyx Pharmaceutical Inc.Taysha Gene Therapies, Inc.
04
Financials
- Market cap
- $223.6M
- Total revenue
- $5.8M
- Enterprise value
- $96.6M
Beyond the preview
Go deeper on Abeona Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abeona Therapeutics Inc..